STRs when to apply histology codes 8085 and 8086
STRs when to apply histology codes 8085 and 8086
Please refer to the most current Solid Tumor Rules site-specific histology tables when assigning HPV-related histology codes, as these codes do not apply to all primary cancer sites.
The guide below is intended to assist with assigning HPV-specific histology codes, including information on the year of implementation and the applicable primary sites. Always ensure histology coding aligns with the latest standards and site-specific guidance.
Cases diagnosed before 1/1/2022:
· p16 positive is not equivalent to HPV positive (pre-2022)
· p16 negative is not equivalent to HPV negative (pre-2022)
Note: HPV-negative is not equivalent to HPV mediated (p16-). According to the 2018 SEER
According to the manual, HPV type 16 refers specifically to a virus subtype and is not the same as p16 overexpression (p16 positive). HPV status must be determined using tests that directly detect viral DNA or RNA, such as ISH, PCR, or RT-PCR. In contrast, p16 testing, which uses IHC, serves as a surrogate marker for HPV but does not detect the virus itself.
To assign the histology code 8086 (SCC, HPV-negative), HPV must be confirmed negative by a viral detection method (ISH, PCR, or RT-PCR). Starting with cases diagnosed January 1, 2022, and forward, p16 IHC test results may be used to assign:
8085 for squamous cell carcinoma, HPV-positive (p16 positive)
8086 for squamous cell carcinoma, HPV-negative (p16 negative)
Here is a summary of the guidelines for assigning histology codes 8085 (SCC, HPV-positive) and 8086 (SCC, HPV-negative), based on year of diagnosis, testing method, and applicable primary sites:
Year
Primary Sites
2022
Cases diagnosed 1/1/2022 forward:
Beginning with cases diagnosed 1/1/2022 forward, p16 test results can be used to code squamous cell carcinoma, HPV positive (8085) and squamous cell carcinoma, HPV negative (8086).
Cases diagnosed 1/1/2018 to 12/31/2021:
Squamous cell carcinoma, HPV positive (8085), and squamous cell carcinoma, HPV negative (8086) are coded only when HPV status is determined by tests based on ISH, PCR, or RT-PCR technologies to detect viral DNA or RNA. p16 is not a valid test to assign these codes.
Oropharynx, Base of Tongue, Tonsils, Adenoids:
C100- C109
C019 Base of tongue
C024 Lingual tonsil
Tonsils:
C090- C111
HPV-related multiphenotypic sinonasal carcinoma 8483/3
• C300- C319
2022
Adenocarcinoma, HPV-associated 8483/3
Adenocarcinoma, HPV-independent
8484/3
Adenocarcinoma, HPV-independent,
gastric type 8482/3
Adenocarcinoma, HPV-independent, clear
cell type 8310/3
Adenocarcinoma, HPV-independent,
mesonephric type 9110/3
Squamous cell carcinoma, HPV-associated 8085/3
Squamous cell carcinoma, HPV-independent 8086/3
Additional Notes
HPV 16 (virus subtype) ≠ p16 overexpression
Adenocarcinoma in situ of the cervix (HPV-associated or not) is not reportable to FCDS.
Endometrioid intraepithelial neoplasia (8380/2) is reportable.
Cervix
C530- C539
2023
When the diagnosis is a subtype/variant of squamous cell carcinoma and HPV status is also noted, ignore the HPV status and code the subtype/variant. EXCEPTION: When keratinizing or non-keratinizing SCC are included in the diagnosis with HPV status, code the appropriate HPV histology: 8085 or 8086
Anus
C210- C218
2023
Vulva
C510- C519
Adenocarcinoma, HPV-associated 8483/3
C529 Vagina NOS; vaginal vault; fornix of vagina; Gartner duct; hymen
2024
Definition of HPV-associated SCC: invasive keratinizing carcinoma arising from penile mucosal or cutaneous compartments that is associated with HPV infection.
Penis and Scrotum
C600- C632
Click on the tags below to see related article: